DSIP 5mg

What is DSIP (Delta Sleep-Inducing Peptide)?

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of approximately 848.81 Da. First isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits subjected to electrically induced sleep, DSIP was initially characterized as a candidate sleep-promoting factor due to its ability to enhance delta-wave (slow-wave) EEG activity (Graf & Kastin, 1984).

DSIP belongs to no known peptide family—its structure is distinct from any other characterized neuropeptide group. It has been detected via radioimmunoassay (RIA) and immunohistochemistry in the brain, peripheral organs, and blood plasma of multiple mammalian species, including rats, rabbits, and humans. DSIP-like immunoreactivity has been identified in specific hypothalamic nuclei, suggesting a role in neuroendocrine regulation beyond sleep alone (Kovalzon & Strekalova, 2006).

Research has revealed that DSIP possesses a remarkably broad spectrum of biological activity. Beyond its namesake sleep-promoting effects, published studies indicate it modulates stress response, pain perception, hormone secretion, circadian rhythms, and free radical metabolism. This multifunctional profile has made DSIP a subject of continued scientific interest for researchers exploring peptides for brain health and neurological regulation.

Mechanism of Action

The precise mechanism of action of DSIP remains one of the most intriguing puzzles in neuropeptide research. Unlike many well-characterized peptides, no specific DSIP receptor has been cloned or isolated, and the gene encoding DSIP has not been definitively identified. Nonetheless, decades of research have established several key pathways through which DSIP exerts its biological effects (Graf & Kastin, 1986).

Neuromodulatory Pathways

Research suggests DSIP modulates multiple neurotransmitter systems simultaneously. In the brain, DSIP appears to interact with glutamatergic signaling, potentially involving NMDA receptor pathways. Studies in rat brain tissue have demonstrated that DSIP partially restricts stress-induced changes in mitochondrial monoamine oxidase type A (MAO-A) activity and serotonin levels, indicating a direct influence on monoaminergic neurotransmission (Prudchenko et al., 1995). This modulation of serotonin metabolism may contribute to both its sleep-promoting and mood-regulating properties.

Pineal Gland and Circadian Regulation

DSIP has been shown to modulate pineal N-acetyltransferase activity—the rate-limiting enzyme in melatonin biosynthesis—through involvement of the α1-adrenergic receptor (Graf & Kastin, 1987). This interaction with the pineal gland places DSIP at a critical juncture in circadian regulation, suggesting it may influence the timing and quality of sleep onset through endogenous melatonin modulation rather than through direct sedation.

Endocrine Modulation

DSIP demonstrates significant neuroendocrine activity. Intracerebroventricular administration of DSIP in rat models stimulates growth hormone (GH) release in a dose-dependent manner, an effect mediated hypothalamically via a dopaminergic mechanism that can be blocked by the dopamine receptor antagonist pimozide (McCann et al., 1987). Additionally, DSIP stimulates luteinizing hormone (LH) release via a hypothalamic site of action (Sahu & Kalra, 1987). These hormonal effects link DSIP to broader physiological processes including tissue repair, reproductive function, and metabolic homeostasis.

Opioidergic System Interaction

Research has established that DSIP interacts with the endogenous opioid system. Centrally administered DSIP produces antinociceptive effects at the supraspinal level, an activity mediated via opioid receptors, as demonstrated by its sensitivity to the opioid antagonist naloxone (Nakamura et al., 1988). Furthermore, DSIP stimulates the release of immunoreactive Met-enkephalin, an endogenous opioid peptide, providing a mechanistic basis for its analgesic properties (Nakamura et al., 1989).

Research Applications

DSIP has been the focus of diverse research investigations spanning sleep science, stress physiology, pain management, neuroprotection, and endocrine regulation. The following sections summarize the primary areas of active research interest.

Sleep Architecture and Insomnia Research

The most extensively studied application of DSIP is its effect on sleep architecture. In animal models including rabbits, rats, and mice, DSIP administration consistently enhances delta-wave (slow-wave) sleep, the deepest and most restorative stage of non-REM sleep. In cats, the effect on REM sleep was more pronounced, demonstrating species-specific responses (Graf & Kastin, 1984). Clinical pilot studies in human subjects with chronic insomnia have demonstrated that DSIP administration improved sleep quality and normalized sleep patterns. In one double-blind study, DSIP enhanced sleep efficiency in 16 chronic insomniac patients (Schneider-Helmert & Schoenenberger, 1992). A separate study in middle-aged and elderly insomniacs showed that sleep improvements persisted beyond the treatment period (Schneider-Helmert, 1987). DSIP is notably distinct from conventional sedatives in that it does not suppress cognitive function or produce hangover effects—rather, it appears to normalize the physiological sleep-wake cycle. This makes it a subject of particular interest among researchers studying peptides for brain health research.

Stress Response and Antioxidant Activity

DSIP demonstrates pronounced stress-protective properties. In rat models subjected to cold stress, DSIP administration shifted the prooxidant-antioxidant balance by increasing the activities of key antioxidant enzymes—superoxide dismutase (SOD), catalase, glutathione peroxidase, and glutathione reductase—while also elevating concentrations of reduced glutathione (Bondarenko et al., 2001). Under hypoxic stress conditions, DSIP partially restricted stress-induced changes in MAO-A activity and serotonin levels in rat brain tissue, suggesting a neuroprotective role during metabolic stress (Prudchenko et al., 1995). These findings position DSIP as a research compound of interest for investigating endogenous stress-buffering mechanisms and oxidative damage, relevant to peptides for inflammation research.

Pain Modulation and Analgesic Research

The analgesic properties of DSIP have been documented in both animal and clinical studies. Central administration of DSIP in rodent models produces potent antinociceptive effects at the supraspinal level, mediated through opioid receptor activation and stimulation of endogenous Met-enkephalin release (Nakamura et al., 1988). A clinical pilot study by Larbig et al. demonstrated that DSIP significantly lowered pain levels in 6 out of 7 patients with chronic, pronounced pain episodes after intravenous administration over a series of sessions (Larbig et al., 1984). These findings are of interest alongside other research into peptides for inflammation and pain.

Neuroprotection and Stroke Recovery

A 2021 study by Tukhovskaya et al. investigated the effect of intranasal DSIP administration on motor function recovery following focal stroke induced by middle cerebral artery occlusion in Sprague-Dawley rats. Animals treated with DSIP at 120 µg/kg daily for 8 days showed significantly accelerated recovery of motor coordination in rotarod testing compared to vehicle-treated controls (Tukhovskaya et al., 2021). The motor function recovery may be associated with DSIP's effects on glutamate and GABA receptors, as well as improved cerebral blood supply in stressed brain tissue.

Endocrine and Hormone Research

DSIP modulates the secretion of several key hormones. Studies indicate a dose-dependent stimulation of growth hormone (GH) release via a hypothalamic dopaminergic mechanism (McCann et al., 1987). Evidence further supports a role for DSIP in slow-wave sleep-related GH release, linking sleep architecture to the pulsatile patterns of GH secretion (Iyer et al., 1988). DSIP also stimulates LH but not FSH release via a hypothalamic mechanism (Sahu & Kalra, 1987). Additionally, DSIP has been reported to modulate ACTH and cortisol levels, findings that are of interest in relation to the broader study of growth hormone-releasing peptides.

Published Research Studies

The following are key published studies that have shaped our understanding of DSIP's biological activity:

1. Graf & Kastin (1984) — Comprehensive Review
Published in Neuroscience & Biobehavioral Reviews, this foundational review established DSIP as a nonapeptide of MW ~849 that induces mainly delta-sleep in rabbits, rats, mice, and humans. The authors documented DSIP-like immunoreactivity in the brain and peripheral organs and catalogued its effects on electrophysiology, neurotransmitter levels, circadian patterns, and hormonal activity (PMID: 6145137).

2. Schneider-Helmert & Schoenenberger (1992) — Double-Blind Insomnia Trial
This matched-pairs, double-blind study examined DSIP's effects in 16 chronic insomniac patients. Results indicated improvements in sleep quality and efficiency compared to placebo, with researchers noting that DSIP appeared to normalize sleep patterns rather than induce sedation (PMID: 1299794).

3. Bondarenko et al. (2001) — Antioxidant and Stress Protection
Published in a biochemistry journal, this study demonstrated that DSIP administration at 12 µg/100 g body weight in rats increased the activities of SOD, catalase, glutathione peroxidase, and glutathione reductase. Under cold stress conditions, DSIP restored the prooxidant–antioxidant balance by normalizing enzyme activities and elevating antioxidant concentrations (PMID: 11421812).

4. Larbig et al. (1984) — Chronic Pain Pilot Study
Published in European Neurology, this clinical pilot study administered DSIP intravenously to 7 patients with chronic, severe pain. Six out of seven patients experienced significant reduction in pain levels following a regimen of 5 consecutive daily injections followed by 5 additional injections at 48–72 hour intervals (PMID: 6548970).

5. Tukhovskaya et al. (2021) — Stroke Recovery
Published in Molecules, this recent study showed that intranasal DSIP at 120 µg/kg in SD rats with focal stroke (MCAO model) significantly accelerated motor function recovery. Treated animals demonstrated progressive improvement on rotarod performance testing over a 21-day observation period compared to vehicle controls (PMID: 34500605).

Dosage Protocols in Research

The following information summarizes dosages reported in published research studies and is provided for research purposes only. DSIP is sold strictly as a research chemical and is not intended for human consumption.

Animal Study Dosages

In published animal research, DSIP has been administered via several routes at varying dosages:

• Intraperitoneal injection (rats): 12 µg/100 g body weight for antioxidant and stress-protection studies (Bondarenko et al., 2001).
• Intracerebroventricular injection (rats): 0.1–10 µg for growth hormone stimulation studies, with minimal effective dose at 0.1 µg and a linear log-dose response up to 10 µg (McCann et al., 1987).
• Intranasal administration (rats): 120 µg/kg daily for 8 days in stroke recovery research (Tukhovskaya et al., 2021).

In Vitro Dosages

In dispersed pituitary cell cultures, DSIP produced a dose-related increase in GH release at concentrations from 10⁻¹² M to 10⁻¹⁰ M, with responses declining at higher concentrations (10⁻⁷ and 10⁻⁵ M), demonstrating a bell-shaped dose-response curve characteristic of many neuropeptides (McCann et al., 1987).

Reconstitution Guidelines

For research use, DSIP lyophilized powder is typically reconstituted in bacteriostatic water or sterile saline. Inject the solvent slowly along the wall of the vial and gently swirl until fully dissolved. Avoid vigorous shaking, which may damage the peptide structure. Once reconstituted, the solution should be stored at 2–8°C and used within the timeframe established by your laboratory's stability protocols. Refer to our guide on how to reconstitute peptides for detailed instructions.

Storage and Handling

Proper storage is essential to maintain the integrity and biological activity of DSIP for research applications. The following guidelines are based on established peptide stability principles:

• Lyophilized (unreconstituted) powder: Store at -20°C for long-term storage (up to 24 months). The peptide may also be stored at 2–8°C for shorter periods (up to 3 months) without significant degradation.
• Reconstituted solution: Store at 2–8°C and use within 2–4 weeks. For extended storage of reconstituted DSIP, aliquot the solution into single-use volumes and store at -20°C to avoid repeated freeze-thaw cycles.
• Light and moisture protection: Keep vials in their original sealed packaging and protect from direct light exposure. DSIP is sensitive to oxidation and moisture, so desiccant packets should be maintained with lyophilized stock.
• Handling precautions: Use aseptic technique during reconstitution and aliquoting. Avoid contamination with metal ions, which can catalyze peptide degradation.

For comprehensive peptide storage best practices, consult our detailed guide on how to store research peptides.

Safety Profile in Research

DSIP has been the subject of multiple safety evaluations in both animal and limited clinical research settings. The available evidence suggests a favorable safety profile at the dosages tested in published studies.

In clinical pilot studies involving human subjects with chronic insomnia, DSIP was administered intravenously over multiple sessions without reports of serious adverse effects (Schneider-Helmert, 1983). Unlike conventional sedative-hypnotic drugs, DSIP did not produce residual daytime drowsiness, cognitive impairment, or physical dependence in the study populations examined. The 24-hour sleep-wake behavior study noted efficacy for impaired sleep and daytime functions without significant adverse events (Schneider-Helmert & Schoenenberger, 1987).

In animal research, DSIP administration at doses used for antioxidant studies (12 µg/100 g body weight) and stroke recovery (120 µg/kg daily for 8 days) was well tolerated, with no reported toxicity or mortality attributable to the peptide itself (Tukhovskaya et al., 2021).

It is important to note that DSIP research is still in relatively early stages, and large-scale controlled safety trials have not been conducted. The peptide's effects on hormonal axes—including GH, LH, and cortisol modulation—warrant careful consideration in experimental design. Researchers should also be aware that DSIP's interaction with the opioidergic system, while pharmacologically distinct from opioid agonists, requires appropriate monitoring in relevant study protocols. Researchers are encouraged to review our research peptide safety guide for additional considerations.

Related Peptides

Researchers investigating DSIP often study it alongside other neuropeptides with complementary or overlapping mechanisms of action:

• Selank — A synthetic anxiolytic peptide that modulates GABAergic and serotonergic systems. Like DSIP, Selank demonstrates stress-protective properties and may influence sleep quality through anxiety reduction. A comparison of these two peptides is relevant to researchers studying Selank vs. Semax.
• Semax — A nootropic heptapeptide with neuroprotective properties. While Semax targets cognitive enhancement and BDNF modulation, both Semax and DSIP share neuroprotective research applications, particularly in stroke models.
• Pinealon — A short bioregulatory peptide targeting pineal gland function and melatonin synthesis. As DSIP modulates pineal N-acetyltransferase, Pinealon offers a complementary approach to circadian rhythm and sleep architecture research.
• Epithalon — A tetrapeptide bioregulator of telomerase activity that also influences melatonin production through pinealocyte stimulation. Researchers exploring peptides for anti-aging research often investigate both DSIP and Epithalon for their complementary effects on sleep quality and longevity pathways.

Frequently Asked Questions

What is DSIP used for in research?

DSIP is primarily studied for its effects on sleep architecture, specifically its ability to enhance delta-wave (slow-wave) sleep in animal models and human pilot studies. Additional research applications include stress response modulation, pain perception, antioxidant defense mechanisms, neuroprotection following ischemic injury, and neuroendocrine regulation involving growth hormone, LH, and cortisol.

How does DSIP differ from sedative compounds in research?

Unlike traditional sedative-hypnotic compounds that suppress central nervous system activity broadly, research suggests DSIP normalizes disturbed sleep-wake patterns rather than forcing sedation. Studies indicate DSIP enhances endogenous sleep processes—promoting physiological delta-wave activity—without producing next-day cognitive impairment or physical dependence observed with benzodiazepines and similar compounds.

What is the molecular structure of DSIP?

DSIP is a nonapeptide (nine amino acids) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its molecular weight is approximately 848.81 Da. It belongs to no known peptide family, making its structure unique among characterized neuropeptides. A phosphorylated form (DSIP-P) has also been studied and may possess enhanced biological activity in certain models.

Can DSIP cross the blood-brain barrier?

Research indicates that DSIP can cross the blood-brain barrier, which is significant given its central nervous system effects. Studies using intranasal, intravenous, and intraperitoneal administration routes have all demonstrated central effects, suggesting effective CNS penetration. The intranasal route used in the 2021 stroke recovery study (Tukhovskaya et al., 2021) may offer a practical delivery method for brain-targeted research.

What is the relationship between DSIP and growth hormone release?

Intracerebroventricular injection of DSIP in rat models stimulates GH release in a dose-dependent manner via a hypothalamic dopaminergic mechanism. Additionally, evidence suggests DSIP plays a physiological role in sleep-related GH secretion, linking slow-wave sleep with the pulsatile patterns of GH release that are most active during deep sleep stages (Iyer et al., 1988).

Does DSIP have antioxidant properties?

Yes. Research in rat models has demonstrated that DSIP increases the activity of multiple antioxidant enzymes including SOD, catalase, glutathione peroxidase, and glutathione reductase, while elevating levels of reduced glutathione. Under cold stress conditions, DSIP restored the prooxidant–antioxidant balance that had been disrupted by stress exposure (Bondarenko et al., 2001).

How should DSIP be stored for research use?

Lyophilized DSIP should be stored at -20°C for optimal long-term stability. Once reconstituted in bacteriostatic water or sterile saline, the solution should be refrigerated at 2–8°C and used within 2–4 weeks. Avoid repeated freeze-thaw cycles by aliquoting reconstituted peptide into single-use volumes. For detailed guidance, see our how to store research peptides guide.

Why Buy DSIP from Iron Peak Peptides?

Iron Peak Peptides is committed to providing researchers with the highest-quality DSIP available. Every batch of our DSIP 5mg undergoes rigorous third-party laboratory testing to verify peptide identity, purity (≥99%), and absence of contaminants including heavy metals, endotoxins, and residual solvents. Each order includes a quality assurance documentation with full HPLC and mass spectrometry data, so you can have confidence in the integrity of your research materials.

Our DSIP is manufactured using solid-phase peptide synthesis (SPPS) under cGMP-aligned conditions, ensuring batch-to-batch consistency that is critical for reproducible research outcomes. The lyophilized powder is packaged in sealed, light-protected vials designed to maximize shelf life and minimize degradation during shipping and storage.

With competitive pricing, fast shipping, and dedicated customer support staffed by individuals who understand peptide research, Iron Peak Peptides is the trusted source for DSIP and a full catalog of research peptides. Whether you're studying sleep architecture, neuroprotection, stress physiology, or neuroendocrine regulation, our products provide the foundation for rigorous, reliable science.

References

1. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187.
3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309.
4. Schneider-Helmert D, Schoenenberger GA. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Eur Neurol. 1992;32(1):52.
5. Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1987;26(Suppl 2):97-103.
6. Schneider-Helmert D, Schoenenberger GA. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomniacs. Eur Neurol. 1987;26(Suppl 2):128-134.
7. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. Eur Neurol. 1984;23(5):372-385.
8. Nakamura A, Nakashima M, Sugao T, et al. Potent antinociceptive effect of centrally administered delta sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988;155(3):247-253.
9. Nakamura A, Nakashima M, Kanemoto H, et al. Delta sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices. Brain Res. 1989;480(1-2):11-16.
10. McCann SM, Iyer KS, et al. Delta sleep-inducing peptide (DSIP) stimulates growth hormone (GH) release. Peptides. 1987;8(2):289-298.
11. Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci USA. 1988;85(10):3653-3656.
12. Sahu A, Kalra SP. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Life Sci. 1987;40(12):1201-1206.
13. Graf MV, Kastin AJ. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. J Neurochem. 1987;48(4):1252-1257.
14. Bondarenko TI, Miliutina NP, Shustanova TA, Mikhaleva II. Regulation of free radical processes by delta-sleep inducing peptide in rat tissues under cold stress. Biochemistry (Mosc). 2001;66(6):632-639.
15. Prudchenko IA, Stashevskaya LV, Mikhaleva II, Ivanov VT. Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A and serotonin content under hypoxia stress. FEBS Lett. 1995;368(2):367-369.
16. Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173.
17. Schneider-Helmert D. A clinical trial with DSIP. Eur Neurol. 1983;22(Suppl 1):15-17.